It is essential to select perfusion clones during cell line development (CLD) that thrive in the unique environment of intensified bioprocesses. Such clones have high specific productivity (qP), moderate growth rates, and high volumetric titer and yield. Traditional fed-batch CLD selects for clones that perform well in fed-batch, but this performance may not translate to a perfusion process.
Here, we highlight the advantage of adopting a perfusion-specific CLD process to create more productive clones and provide an integrated solution for intensified processing using the CHOZN® GS-/- cell line, a suite of best-in-class media, and the Mobius® Breez Microbioreactor system.
In this webinar, you will learn:
- How to optimize the CLD process to generate stable, high-performing, perfusion clones.
- How to incorporate perfusion scale-down models into your CLD workflow.
- How the Mobius® Breez can be used to make final clone selection and cost-effectively begin perfusion process development.
- The importance of using the right media for cell line expansion and production during CLD.
Speaker
Vince Balassi
Merck
Scientist, Upstream and Process Materials R&D
Vince Balassi is a Scientist on the expression systems and novel bioprocess materials team at Merck. His goal is to use cell line development and engineering techniques to improve the CHOZN® GS-/- host cell line and enhance the efficiency of expressing biotherapeutics.
He joined Merck in 2015 and has held different positions in manufacturing and R&D. Vince holds an MS in biotechnology from Johns Hopkins University and a BS in microbiology & biotechnology from Missouri State University.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:1h
Language:English
Session 1:presented March 21, 2024
To continue reading please sign in or create an account.
Don't Have An Account?